Clinical Trials Directory

Trials / Unknown

UnknownNCT02943031

The Effect of Individualized Precision Therapy Programs in Patients With BTC

The Effect of Individualized Precision Therapy Programs in Patients With Biliary Tract Cancer

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
RenJi Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a prospective cohort study. Patients who meet the inclusion criteria will be enrolled in this study. The samples of biliary tract tumors will be collected. Genome sequencing, mini-PDX and PDX will be performed according to the requirement of individualized precision therapy programs. Suitable drugs will be chose according to drug screening results. OS and PFS will be compared with traditional chemotherapy to evaluate the effect of individualized precision therapy programs.

Detailed description

In this prospective cohort study, patients who are eligible for inclusion criteria will enroll in the study. After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification, and then to develop individualized precise treatment programs. The investigators hope to achieve the following objectives: ① Through the establishment of Individualized Precision Therapy Programs to improve the overall survival of bile duct malignancy (BTC); ② To study the molecular typing of the prognosis of biliary malignancy; ③ To construct a database of BTC gene bank, as well as for drug screening information.

Conditions

Interventions

TypeNameDescription
OTHERIndividualized Precision Therapy ProgramsAfter bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.

Timeline

Start date
2016-12-01
Primary completion
2020-12-01
Completion
2020-12-01
First posted
2016-10-24
Last updated
2019-10-18

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02943031. Inclusion in this directory is not an endorsement.